Human Pharmaceuticals segment

Eli Lilly & Co.’s (LLY) Human Pharmaceuticals business reported revenues of ~$5.6 billion during the second quarter. This represents 10.0% YoY (year-over-year) revenue growth, compared to the second quarter of 2017.

This revenue growth was driven by a 9.0% increase in volume and a 2.0% positive impact of foreign exchange, partially offset by a marginal decrease due to prices. The chart below compares the revenues of the endocrine franchise’s key products since the first quarter of 2017.

Eli Lilly’s Q2 2018 Earnings: Human Pharmaceuticals Business

Endocrine products

Eli Lilly’s (LLY) endocrine products portfolio includes Humalog, Humulin, Basaglar, Trulicity, Jardiance, Trajenta, and Forteo. During the second quarter, Humalog, Basaglar, Jardiance, and Trulicity reported revenue growth. However, sales of Humulin and Forteo declined, and Trajenta reported nearly flat revenues during the quarter. The company’s endocrine products also include Glucagon, Humatrope, Actos, and Humapen.

Humalog

Humalog products, which are mealtime insulin products, reported 13.0% YoY revenue growth to $769.8 million during the second quarter, compared to ~$678.4 million during the second quarter of 2017. This revenue increase was driven by 19.0% growth in its US sales to $464.5 million due to higher realized prices. This increase was also due to 6.0% growth in international sales to $305.2 million during the second quarter.

Humulin

Humulin products, which are concentrated insulin products, reported revenues of $346.0 million during the second quarter. This represents a 3.0% decrease in YoY revenues compared to the second quarter of 2017. This decline was driven by an 18.0% decrease in international sales and partially offset by a 5.0% increase in its US sales during the quarter.

Forteo

Forteo, an osteoporosis drug, reported revenues of ~$434.5 million during the second quarter. This represents a 3.0% YoY revenue decrease, compared to ~$446.7 million during the second quarter of 2017. The decline in Forteo’s revenues was driven by a 10.0% decrease in its US sales, which was partially offset by 7.0% growth in its international sales during the quarter.

Later in this series, we’ll discuss the performance of Basaglar, Jardiance, Trulicity, and other new drugs in Eli Lilly’s portfolio.

The Invesco Dynamic Pharmaceuticals ETF (PJP) holds 5.2% in Eli Lilly (LLY), 4.9% in Merck & Co. (MRK), 4.8% in Pfizer (PFE), and 4.1% in AbbVie (ABBV).

Latest articles

The future of the T-Mobile and Sprint merger remains unclear. Several state attorneys and Democratic senators have come together to oppose it.

According to President Trump, the US economy is “poised for big growth after trade deals are completed.” Markets are volatile amid the trade war.

Canopy Growth didn't impress investors with its earnings for the first quarter of 2020. The stock has fallen 12.4% since the company's earnings.

President Trump finally seems to acknowledge how the US-China trade war could impact tech giant Apple. Trump met with Apple CEO Tim Cook at a dinner.

As of August 13, HEXO (HEXO) was trading at 6.51 Canadian dollars—a fall of 30.9% since its third-quarter earnings on June 12.

On August 15, in an interview with CNBC, Mark Zandi said that the trade war hurts the US economy. The trade war has a negative impact on certain sectors.